Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial

Summary

This is an open label clinical study to evaluate the activity of chloroquine phosphate in patients with SARS-CoV-2 virus infection. The study aims to document possible prevention of pneumonia in patients staying at home and in improving the symptoms of SARS-CoV-2 pneumonia in patients who will be hospitalised.

Conditions

• Pneumonia, Viral
• Covid-19

Interventions

DRUG

UNIKINON (Chloroquine phosphate) 200mg tablets

Two and a half tablets (500mg) twice daily for seven days.

Sponsors & Collaborators

• Athens General Hospital Hippokrateio

  collaborator UNKNOWN

• Sotiria Thoracic Diseases Hospital of Athens

  collaborator OTHER

• Sismanoglio General Hospital

  collaborator OTHER

• Divine Providence Hospital Pammakaristos

  collaborator UNKNOWN

• AHEPA University Hospital

  collaborator OTHER

• University Hospital, Ioannina

  collaborator OTHER

• Corfu General Hospital Agia Irini

  collaborator UNKNOWN

• Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.

  lead INDUSTRY

Principal Investigators

• Helen Sambatakou, MD · Athens General Hospital "Hippokrateio", 2nd department of Pathology

• Nikolaos Koulouris, MD · Athens General Hospital of Thoracic Diseases "SOTIRIA", 1st University Pulmonary Clinic

• Garyfallia Poulakou, MD · Athens General Hospital of Thoracic Diseases "SOTIRIA", 3rd University Pathology Clinic

• Malvina Lada, MD · General Hospital of Athens "Sismanoglio", 2nd Department of Pathology

• Ioannis Baraboutis, MD · Divine Providence Hospital "Pammakaristos", Pathology Department

• Symeon Metallidis, MD · University General Hospital of Thessaloniki AHEPA, 1st University Pathology Clinic

• Haralambos Milionis, MD · University General Hospital of Ioannina, 1st University Pathology Clinic

• Ilias Papanikolaou, MD · Corfu General Hospital Agia Irini, Pulmonary Clinic

Study Design

Allocation

NA

Purpose

PREVENTION

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-04-06

Primary Completion

2020-11-30

Completion

2020-11-30

Countries

• Greece

Study Locations